Pharmakocinetics of landiolol in patients undergoing cardiac surgery

Pharmakocinetics of landiolol in patients undergoing cardiac surgery - Pharmakocinetics of landiolol in patients undergoing cardiac surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023699

Enrollment

Registered

2016-08-25

Start date

2016-08-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac disease

Interventions

Landiolol was administered at target concentrations of 0.5 and 1.0 mcg/mL for each 30 min at each target concentration.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with body weight of less than 100 kg and ASA physical status 2 - 4

Exclusion criteria

Exclusion criteria: Patients with arrhythmia and patients medicated with alpha-methyldopa or clonidine

Design outcomes

Primary

Measure	Time frame
Plasma concentration of landiolol from the start of administration until 20 min after the end of administration	—

Countries

Japan

Contacts

Public ContactTakayuki Kunisawa

Asahikawa Medical University Anesthesiology and CCM

taka.kunisawa@nifty.ne.jp0166-68-2580

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026